Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
Moleculin Biotech (MBRX) has scheduled its third quarter 2024 financial results announcement for November 8, 2024. The company will host a conference call and webcast to discuss operational and financial results on November 11, 2024, at 8:30 AM ET. Participants can join via phone using the numbers (877) 407-0832 (domestic) or (201) 689-8433 (international). The webcast will be available on the company's website and archived for 90 days.
Moleculin Biotech (MBRX) ha programmato l'annuncio dei risultati finanziari del terzo trimestre del 2024 per l'8 novembre 2024. L'azienda ospiterà una conferenza telefonica e una webcast per discutere i risultati operativi e finanziari l'11 novembre 2024, alle 8:30 AM ET. I partecipanti possono unirsi tramite telefono utilizzando i numeri (877) 407-0832 (nazionale) o (201) 689-8433 (internazionale). La webcast sarà disponibile sul sito web dell'azienda e archiviata per 90 giorni.
Moleculin Biotech (MBRX) ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el 8 de noviembre de 2024. La compañía llevará a cabo una conferencia telefónica y una transmisión en vivo para discutir los resultados operativos y financieros el 11 de noviembre de 2024, a las 8:30 AM ET. Los participantes pueden unirse por teléfono utilizando los números (877) 407-0832 (nacional) o (201) 689-8433 (internacional). La transmisión en vivo estará disponible en el sitio web de la compañía y archivada durante 90 días.
Moleculin Biotech (MBRX)는 2024년 3분기 재무 결과 발표를 2024년 11월 8일로 예정하고 있습니다. 회사는 2024년 11월 11일 오전 8:30 ET에 운영 및 재무 결과에 대해 논의하기 위한 전화 회의 및 웹캐스트를 개최할 것입니다. 참가자들은 (877) 407-0832 (국내) 또는 (201) 689-8433 (국제) 번호를 사용하여 전화로 참가할 수 있습니다. 웹캐스트는 회사 웹사이트에서 제공되며 90일 동안 아카이브됩니다.
Moleculin Biotech (MBRX) a prévu l'annonce de ses résultats financiers du troisième trimestre 2024 pour le 8 novembre 2024. La société tiendra une conférence téléphonique et un webinaire le 11 novembre 2024 à 8h30 ET pour discuter des résultats opérationnels et financiers. Les participants peuvent se joindre par téléphone en utilisant les numéros (877) 407-0832 (national) ou (201) 689-8433 (international). Le webinaire sera disponible sur le site internet de l'entreprise et archivé pendant 90 jours.
Moleculin Biotech (MBRX) hat die Bekanntgabe der Finanzergebnisse für das dritte Quartal 2024 auf den 8. November 2024 festgelegt. Das Unternehmen wird am 11. November 2024 um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten, um die operativen und finanziellen Ergebnisse zu besprechen. Teilnehmer können sich telefonisch unter (877) 407-0832 (national) oder (201) 689-8433 (international) einwählen. Der Webcast wird auf der Unternehmenswebsite zur Verfügung stehen und 90 Tage lang archiviert.
- None.
- None.
Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The live audio webcast will be accessible on the Events page of the Investors section of the Moleculin website, moleculin.com, and will be archived for 90 days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-report-third-quarter-2024-financial-results-on-november-8-2024-and-host-conference-call-and-webcast-302296237.html
SOURCE Moleculin Biotech, Inc.
FAQ
When will Moleculin Biotech (MBRX) release Q3 2024 earnings?
How can I join Moleculin Biotech's (MBRX) Q3 2024 earnings call?